Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVSVΔG-ZEBOV-GP in Ebola Virus Disease
NCT03161366Phase 3Completed
- Sponsor
- Illumina
- Start
- May 2018
- Primary completion
- Jul 2018
- Modality
- Viral Vector Vaccines
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD), sponsored by Illumina. Primary endpoint: Cumulative incidence of Ebola Virus Disease at 84 days. Started May 2018; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT03161366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161366.